Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat ...

Gland Pharma has received USFDA approval for its generic Latanoprostene Bunod Ophthalmic Solution, intended to treat high eye ...

The product is bioequivalent and therapeutically equivalent to the reference listing drug VYZULTA Opthalmic solution, 0.024% ...

Hyderabad: Gland Pharma Limited, a generic injectable & ophthalmic focused pharmaceutical company, has announced that the ...

AM(IST)on Friday in an upbeat market. Laurus Labs Ltd.(up 2.46 per cent), Granules India Ltd.(up 1.63 per cent), Gland Pharma ...

Gland Pharma receives USFDA approval for its generic Latanoprostene Bunod Ophthalmic Solution, a bioequivalent to Bausch and ...

Although the Nifty Pharma index has gained 5.5% over the last one month, the index is down 10.7% so far on a year-to-date basis. Pharma stocks did see some recovery over the last one month as reports ...

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Latanoprostene Bunod Ophthalmic Solution, 0.024%.

February 3, 2025 India's Gland Pharma reports higher Q3 profit as expenses drop Indian generic injectables maker Gland Pharma reported a 7% rise in third-quarter profit on Monday, as lower ...

Gland Pharma, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹1445. The stock has experienced fluctuations today, with a low of ...

The ophthalmic solution is used to decrease intraocular pressure in open-angle glaucoma or ocular hypertension patients.